Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Clin Immunol. 2010 Jul;6(4):621-31. doi: 10.1586/eci.10.36.

Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Author information

  • 1Division of Gastroenterology, Hospital of University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.

Abstract

The care of inflammatory bowel disease has changed considerably with the introduction of a number of immunosuppressants including anti-metabolite and anti-TNF therapies. While efficacious, these medications also carry important risks, notably the potential risk of lymphoma. This risk is one of the most worrisome for both patients and physicians. Our current knowledge is still evolving; however, our understanding of what risks these drugs carry, both individually and synergistically, is critical in allowing informed decision making. In this article, we will describe the known lymphoma risks of commonly used immunosuppressant medications in inflammatory bowel disease, with an emphasis on non-Hodgkin's lymphoma and hepatosplenic T-cell lymphoma.

PMID:
20594135
[PubMed - indexed for MEDLINE]
PMCID:
PMC2925472
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk